AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts

Abcellera Biologics, Inc. ((ABCL)) has held its Q4 earnings call. Read on for the main highlights of the call.

AbCellera Biologics’ latest earnings call struck a cautiously optimistic tone as management framed 2025 as a pivotal year in its transition to a clinical‑stage biotech. Executives highlighted robust liquidity, advancing internal drug candidates and approaching clinical catalysts, while openly acknowledging elevated cash burn, non‑recurring revenue drivers and clinical risks that could slow value realization.

Strong Liquidity Underpins Strategic Shift

AbCellera closed FY2025 with about $561 million in cash, cash equivalents and marketable securities, supplemented by roughly $140 million in committed government funding. This brings total available liquidity to around $700 million, giving the company ample runway to fund its multi‑year pivot toward internally owned drug programs despite ongoing operating losses.

Transition to Clinical-Stage Biotech and Pipeline Expansion

Management reported delivering on four strategic priorities for 2025 and surpassing one by nominating two development candidates instead of one. Lead asset ABCL635 moved into a randomized, double‑blind, placebo‑controlled Phase II study, while ABCL575 is in Phase I and ABCL688 and ABCL386 are in IND‑enabling work, with more than 20 programs still in discovery.

Building a Roadmap of Near- and Mid-Term Catalysts

Investors were given a clearer line of sight to value drivers, with two clinical readouts expected in 2026, including ABCL635’s Phase II data in the third quarter. Management also anticipates multiple catalysts in 2027, targeting five clinical‑stage programs by mid‑2027 as the pipeline matures and additional assets enter first‑in‑human trials.

Revenue Growth Masked by One-Off Legal Settlement

Total revenue jumped to $75 million in 2025 from about $29 million in 2024, a year‑over‑year increase of roughly 159%. However, a significant portion of this growth was driven by $36 million from a patent settlement with Bruker, underscoring that much of the gain was non‑recurring rather than evidence of sustained commercial momentum.

Improved Net Loss and Earnings Per Share Trend

Despite heavy investment, the company modestly narrowed its losses, with net loss improving to approximately $146 million from about $163 million a year earlier. Loss per share came in at $0.49, signaling some progress on the bottom line even as AbCellera leans into funding its internal pipeline and manufacturing capabilities.

Stepped-Up R&D to Advance Internal Pipeline

Research and development expenses rose to $187 million in 2025, about $20 million higher than the prior year, reflecting a deliberate choice to invest in proprietary assets. Management framed the roughly 12% increase as essential to building a differentiated portfolio and transitioning away from a fee‑for‑service discovery model.

Manufacturing Build-Out and Capital Investments

The company reported substantial completion of its clinical manufacturing facility, along with continued property, plant and equipment spending to support in‑house production. These investments, along with real estate and financing actions that added $63 million of liquidity in the quarter, are aimed at tightening supply chain control, enhancing flexibility and strengthening intellectual property protection.

Discovery-to-Clinic Track Record with Partners

AbCellera emphasized its cumulative record of 104 partner‑initiated programs with downstream economics, with 19 molecules discovered by or via its technology already in the clinic. Of the 104 programs, around 48 are actively progressing, underscoring continued partner engagement even as the company’s focus tilts toward its own internal candidates.

Revenue Concentration and One-Time Drivers

While licensing and royalty revenue reached $47 million in 2025, management highlighted that $36 million of this figure came from the Bruker settlement. This concentration underscores that the impressive revenue expansion is partly an artifact of legal resolution and may not be indicative of the company’s ongoing revenue trajectory.

Pressure from Declining Research Fee Revenues

Management cautioned that research fee revenues are expected to trend lower as the business pivots away from partner‑initiated discovery projects. This shift could create near‑term headwinds for top‑line growth but is positioned as a trade‑off to prioritize higher‑value, longer‑duration economics from AbCellera‑owned programs.

Persistent Net Loss and Cash Burn Profile

Operating activities consumed approximately $130 million of cash during 2025, leaving the company firmly in loss‑making territory as it scales its pipeline. With a net loss of about $146 million and rising operating costs, investors will be watching how quickly pipeline milestones can begin to offset the current pace of cash consumption.

Rising R&D Spend and Near-Term Cash Needs

The roughly $20 million year‑over‑year increase in R&D, up to $187 million, reinforces that AbCellera is front‑loading investment into its portfolio. While these expenditures raise near‑term funding needs, management argues they are critical for getting multiple shots on goal into the clinic and ultimately converting scientific assets into commercial opportunities.

Clinical Risk Surrounding Lead Program ABCL635

Management acknowledged that ABCL635, while supported by encouraging biomarker data, still faces significant uncertainty due to an incomplete understanding of hot‑flash biology. A negative Phase II readout in Q3 2026 could materially delay AbCellera’s emergence as a late‑stage company and would likely reset expectations for its broader clinical strategy.

Heightened Scrutiny in the OX40 Ligand Class

The company also addressed a safety event in the broader OX40/OX40L class, which has drawn regulatory attention after an external Kaposi sarcoma case. While AbCellera downplayed direct implications for its OX40L asset ABCL575, such class‑level developments could raise the bar for safety monitoring and slow advancement timelines.

Reduced Transparency on Partner Program Activity

Starting in 2026, AbCellera will no longer disclose partner‑initiated program starts on a quarterly basis, limiting visibility into a key element of discovery activity. Investors focused on partner momentum may find it harder to track the underlying run‑rate of new collaborations, even as management shifts the narrative toward internal pipeline progress.

Guidance and Outlook: Catalysts Ahead Amid Investment Phase

Looking forward, AbCellera is guiding to two clinical readouts in 2026, led by ABCL635’s Phase II data and ABCL575’s Phase I results, with plans to start trials for ABCL688 and ABCL386 in 2027 and reach five clinical‑stage programs by mid‑2027. Financially, management signaled that the sizeable cash balance and government funding should comfortably support elevated R&D and manufacturing spend through this catalyst‑rich period.

AbCellera’s earnings call painted the picture of a company firmly in investment mode, trading near‑term profitability and clean revenue growth metrics for strategic progress in its pipeline and infrastructure. For investors willing to tolerate clinical and execution risk, the story now hinges on whether upcoming readouts, particularly ABCL635 in 2026, can validate the platform and unlock the value embedded in its substantial liquidity and expanding clinical portfolio.